DailyIQ
|
Last updatedjust now

TEM·Tempus AI Inc. Class A

$71.98
-11.57 (-13.85%)
Pre-Market
High
$72.25
Open
$72.18
Market Cap
12.99B
52W High
$104.32
Low
$71.29
P. Close
$71.98
P/E
-
52W Low
$40.77
Fwd P/E
-8864.53
DailyIQ Est.
$72.44
Inst. Ownership
2.8%
Short Interest
15.41%
Days to Cover
5.2
Technical Score (1D)
59
BULLISH
News Sentiment
68
BULLISH
On Oct 6, Tempus AI (TEM) secured FDA 510(k) clearance for its Tempus ECG‑MR AI platform, a tool designed to detect early mitral regurgitation, and the approval spurred a 9 % rise in the company’s shares to $83.55. Analysts reported that the clearance was viewed as a catalyst for renewed investor interest, positioning TEM above average analyst targets and suggesting a potential upside in fair value. The approval underscored TEM’s progress in delivering clinically validated AI solutions, strengthening its competitive stance in the healthcare AI market. On Oct 5, the company also obtained 510(k) clearance for its Tempus ECG‑MR and Tempus ECG‑PH AI‑enabled ECG analysis tools, expanding its cardiovascular portfolio. These tools detect moderate or severe mitral regurgitation and pulmonary hypertension from standard 12‑lead ECGs, providing binary diagnostic outputs. The AI‑ECG market is projected to grow from $2.01 billion in 2025 to $2.40 billion in 2026, a 19.3 % CAGR, positioning TEM to capture a larger share of this expanding segment.
LOW TARGET
$35 -51.3%
2 analysts
MEAN TARGET
$70 -2.6%
12 analysts
HIGH TARGET
$100 +39.1%
9 analysts
PRICE RANGE
$35.00 - $100.00
SB / B / H / S / SS
6/7/8/1/1
DAILYIQ EST.
$72.44 (+0.8%)
Bought (1Y)
0 shares
$0
Sold (1Y)
1,724,414 shares
$104.3M
Schoenherr Thomas EdwardCEO, Diagnostics
Sell10,281 shares2026-09-25
LEFKOFSKY ERIC PCEO and Chairman
Sell160 shares2026-09-22
LEFKOFSKY ERIC PCEO and Chairman
Sell14,042 shares2026-09-22
LEFKOFSKY ERIC PCEO and Chairman
Sell29,367 shares2026-09-22
LEFKOFSKY ERIC PCEO and Chairman
Sell6,431 shares2026-09-22
View full insider trading history →
32/ 100
Bearish
Overall: Bearish
✓Revenue growing year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-19.3%
Revenue CAGR
58.3%
Current Ratio
3.13x
Return on Equity
-49.9%
View full financials →

EPS

EstBeatMiss
$-0.19$-0.16$-0.13$-0.10$-0.07Q3'25Q3'26
QtrEstActual+/−
Q3'26$-0.08 - -
Q3'25$-0.18$-0.11+37.3%

Revenue

EstBeatMiss
$322M$348M$374M$400M$426MQ3'25Q3'26
QtrEstActual+/−
Q3'26$414M - -
Q3'25 - $334M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

TEM Stock Snapshot

NEUTRAL59/100
$71.32−$1.38 (1.9%)
Market cap
12.99B
Day range
$71.29 – $72.25
News sentiment
68/100 · Bullish
Analyst target
$70.06 (-1.8%)
Consensus
Hold · 23 analysts
52-week range+74.9% off low · -31.6% from high
$40.77$104.32
Price $71.32 DailyIQ Est. $72.44

TEM sits in the middle of its 52-week range with the technical picture unresolved. Earnings and guidance carry more weight than macro data at this capitalisation.

Behaviour On Record

What TEM's own history says about today's numbers

Realized volatility (21d)
78.9% 47th pct
vs 200-day average
+48.2%
Up days (1y)
45%

Tempus AI Inc. Class A is currently running 78.9% annualised volatility over the last 21 sessions. Measured against TEM's own 2 years of daily returns rather than a market-wide average, that is the 47th percentile — close to its own typical level, against a typical reading of 80.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

Price sits +48.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 94th percentile — a wider gap than this stock usually carries. Over the past year TEM closed higher on 45% of sessions, and it is currently 2 sessions into a rising streak.

Overnight risk is measurable too: TEM has opened more than 2% away from the prior close in 66 of 577 sessions (11.4% of the time), with the largest gaps running +16.1% and -7.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 578 daily closes between 2024-06-14 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against TEM's own 2-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of TEM's sector?

Tempus AI Inc. Class A sits in the Software sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Software industry group, TEM ranks 2nd of 15 tracked industries, leading.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
100
Industry rank
#2 of 15

Analyst Rating Changes

Are analysts turning bullish or bearish on TEM?

Guggenheim most recently reiterated its rating on Tempus AI Inc. Class A to Buy on Oct 1, 2026 with a price target of $92 (from $65). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
Guggenheim — Buy
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 1, 2026GuggenheimMaintainedBuy$65 → $92
Sep 21, 2026Goldman SachsInitiatedNeutral$75
Sep 11, 2026HC Wainwright & Co.MaintainedBuy$56 → $66
Sep 9, 2026UBSInitiatedNeutral$70
Sep 8, 2026Rothschild & CoInitiatedNeutral$67
Sep 8, 2026Roth CapitalInitiatedNeutral$67
Sep 2, 2026Cantor FitzgeraldInitiatedOverweight$80
Sep 1, 2026Piper SandlerUpgradeNeutral → Overweight$56 → $76
Aug 31, 2026Freedom Capital MarketsMaintainedHold$51 → $73
Aug 20, 2026BTIGMaintainedBuy$70 → $80
Aug 4, 2026Piper SandlerMaintainedNeutral$58 → $56
Aug 3, 2026BTIGMaintainedBuy$80 → $70

Held by These ETFs

TEM is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.

News Sentiment Analysis

Sentiment gathered from recent headlines

68/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
On October 6, the U.S. Food and Drug Administration granted 510(k) clearance to Tempus AI’s ECG‑MR, an AI system for early detection of mitral regurgitation. The approval coincided with a 9% intraday rise in TEM shares, lifting the price to $83.55 and contributing to a 29% month‑to‑date gain. The clearance signals regulatory validation for the company’s product pipeline and may enhance investor confidence, although the year‑to‑date shareholder return remains negative. The move underscores TEM’s progress toward commercial deployment of its AI diagnostics platform.
What did this article say?
Tempus AI (TEM) obtained 510(k) FDA clearance for its Tempus ECG-MR and Tempus ECG-PH AI‑enabled ECG analysis tools, expanding its cardiovascular portfolio. The new products detect moderate or severe mitral regurgitation and pulmonary hypertension from standard 12‑lead ECGs, providing binary diagnostic outputs. The AI‑ECG market is projected to grow from $2.01 billion in 2025 to $2.40 billion in 2026, a 19.3% CAGR, positioning TEM to capture a larger share of this expanding segment.
What did this article say?
Tempus AI, Inc. (NASDAQ: TEM) announced that 13 abstracts were accepted for presentation at the European Society for Medical Oncology Congress 2026. The abstracts covered solid tumors such as prostate, breast, NSCLC, renal cell carcinoma, and gynecologic cancers, showcasing research on cancer biology, treatment response, and patient outcomes. The company highlighted its AI-enabled technology and product offerings, including Tempus Lens and Tempus One, at booths #1068 and #1069. These presentations aim to inform biomarker development, patient stratification, and clinical trial design.
What did this article say?
Guggenheim analyst Subbu Nambi maintained a Buy rating on Tempus AI (NASDAQ:TEM) and raised the price target from $65 to $92. The upgrade reflects confidence in the company’s growth prospects and valuation. The move signals a positive outlook for investors and may support the stock’s price trajectory.
What did this article say?
Analysts warned that Personalis shareholders remain exposed to downside in TEM shares following the merger, with limited upside beyond a $48.42 threshold. The report highlighted that Personalis’s standalone value is less relevant, as the merger’s impact on TEM stock is the primary concern. Investors were cautioned that the merger could constrain further appreciation of TEM shares.
What did this article say?
Providence Therapeutics Holdings announced the creation of its first Clinical Advisory Board to guide its mRNA cancer vaccine initiatives. The board will focus on the company’s personalized vaccine for pediatric brain cancer and its off‑the‑shelf precision therapies for solid tumors. The move signals a strategic effort to accelerate development and clinical translation of its oncology programs.
What did this article say?
On September 28, Tempus AI (TEM) announced that the FDA granted 510(k) clearance for its Tempus ECG‑MR, an artificial intelligence system that analyzes standard 12‑lead ECGs to identify moderate or severe mitral regurgitation. The clearance positions the product as an early detection tool for high‑risk patients who may otherwise remain undiagnosed until advanced disease. The approval expands TEM’s portfolio of AI‑driven cardiac diagnostics and could broaden its market reach in the cardiovascular diagnostics space.
What did this article say?
On September 28, Tempus AI (TEM) announced that the FDA granted 510(k) clearance for its new ECG‑MR AI product, which analyzes 12‑lead resting ECGs to detect signs of undiagnosed moderate or severe mitral regurgitation. The clearance makes ECG‑MR the fourth FDA‑cleared product in TEM’s ECG‑AI line, covering arrhythmia, heart function, pulmonary vascular and valvular disease. The approval is expected to enhance early detection of mitral regurgitation, potentially improving patient outcomes and expanding TEM’s market presence.
What did this article say?
On September 28, TEM announced that its ECG-MR AI product received FDA 510(k) clearance. The clearance marks the fourth FDA-approved Tempus ECG-AI solution, expanding the company’s portfolio into valvular disease detection. The tool analyzes standard 12‑lead resting ECGs to identify signs of undiagnosed mitral regurgitation, potentially improving early diagnosis and patient outcomes. This regulatory approval is expected to enhance TEM’s market position and support future product rollouts.
What did this article say?
On September 17, 2026, Tempus AI Chief Accounting Officer Ryan M. Bartolucci sold 7,062 shares of TEM under a Rule 10b5‑1 trading plan. The transaction occurred at a weighted average price of $75.00, slightly below the closing price of $80.36 that day. The sale reduced his direct holdings to 60,804 shares, while the company’s year‑to‑date return was a modest -7%. The move follows a 30% rebound in the stock earlier in the year, but the insider sale may signal a lack of confidence in near‑term performance.

Technical Analysis

Real-time indicators across multiple timeframes

59
NEUTRAL
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
1 tracked managers · $293.77M combined position · 0 adding, 0 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Citadel Advisors LLC• Hold5,071,2012.79%$293.77M2026-09-02
Q2 2026 flow:5.07M sh bought ($293.77M)0 sh sold ($0)net +5.07M sh (+$293.77M)
View full institutional holdings history →

Discover More

CTSH
Cognizant Technology Solutions Corporation
$57.23
+0.03%
NFLX
Netflix, Inc.
$69.03
-0.22%
FWONA
Liberty Media Corporation - Series A Liberty Formula One
$87.73
-0.13%
SNOW
Snowflake Inc.
$335.13
+0.00%
CSGP
CoStar Group, Inc.
$27.52
-0.94%
FROG
JFrog Ltd.
$98.45
-0.13%
ORCL
Oracle Corporation
$142.85
-1.57%
VRSK
Verisk Analytics, Inc.
$165.20
-0.05%
BSY
Bentley Systems Incorporated Class B
$35.83
-0.33%
NOW
ServiceNow, Inc.
$138.02
+0.11%